Karyopharm Therapeutics(KPTIQ)
$0.020.00 (0.00%)
KPTIQ
Karyopharm Therapeutics stock forecast
$0.02
At close:0.00 (0.00%)
Want to see KPTIQ full AI Analyst Report?
Karyopharm Therapeutics (KPTIQ) Stock Forecast & Price Target
1,272 Followers
KPTIQ Analyst Ratings
Moderate Buy
2Buy1Hold0Sell
Based on 3 analysts giving stock ratings to Karyopharm Therapeutics in the past 3 months
KPTIQ Stock 12 Month Forecast
Average Price Target
$5.84â–²(34252.94% Upside)Based on 3 Wall Street analysts offering 12 month price targets for Karyopharm Therapeutics in the last 3 months. The average price target is $5.84 with a high forecast of $8.00 and a low forecast of $3.68. The average price target represents a 34252.94% change from the last price of $0.02.
Past 12 Months12 Month ForecastJan2026Oct2026
High$8.00
Average$5.84
Low$3.68
Highest Price TargetHighest$8.00Average Price Target$5.84Lowest Price TargetLowest$3.68
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Michael King | Rodman & Renshaw | ― | hold | ― | Downgraded | 11/02/26 | ||
| Brian Abrahams | RBC Capital | $8 | buy | 46958.82%Upside | Reiterated | 10/27/26 | ||
| Yanni Souroutzidis | Cantor Fitzgerald | $3.68 | buy | 21547.06%Upside | Reiterated | 09/01/26 | ||
| Robert Burns | H.C. Wainwright | $13→$3 | hold | 17547.06%Upside | Downgraded | 07/31/26 | ||
| Edward Tenthoff | Piper Sandler | $16→$7 | buy | 41076.47%Upside | Reiterated | 07/31/26 | ||
| Colleen M. Kusy | Robert W. Baird | ― | hold | ― | Downgraded | 07/31/26 | ||
| Maury Raycroft | Jefferies | $14→$11 | buy | 64605.88%Upside | Reiterated | 07/31/26 | ||
 Unknown AnalystNot Ranked | Leerink Partners | $5→$7 | hold | 41076.47%Upside | Reiterated | 05/15/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Michael KingRodman & Renshaw | HoldDowngraded | 11/02/26 | ― | ||
| Brian AbrahamsRBC Capital | BuyReiterated$8 | 10/27/26 | 46958.82%Upside | ||
| Yanni SouroutzidisCantor Fitzgerald | BuyReiterated$3.68 | 09/01/26 | 21547.06%Upside | ||
| Robert BurnsH.C. Wainwright | HoldDowngraded$13→$3 | 07/31/26 | 17547.06%Upside | ||
| Edward TenthoffPiper Sandler | BuyReiterated$16→$7 | 07/31/26 | 41076.47%Upside | ||
| Colleen M. KusyRobert W. Baird | HoldDowngraded | 07/31/26 | ― | ||
| Maury RaycroftJefferies | BuyReiterated$14→$11 | 07/31/26 | 64605.88%Upside | ||
| Unknown AnalystLeerink PartnersNot Ranked | HoldReiterated$5→$7 | 05/15/26 | 41076.47%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Karyopharm Therapeutics
3 Months
Success Rate0/0 ratings generated profit
―
Average Return
―
Copying Edward Tenthoff's trades and holding each position for 3 Months would result in ― of your transactions generating a profit, with an average return of ― per trade.
1 Year
Success Rate0/0 ratings generated profit
―
Average Return
―
Copying Brian Abrahams's trades and holding each position for 1 Year would result in ― of your transactions generating a profit, with an average return of ― per trade.
2 Years
Success Rate0/0 ratings generated profit
―
Average Return
―
Copying Maury Raycroft's trades and holding each position for 2 Years would result in ― of your transactions generating a profit, with an average return of ― per trade.
KPTIQ Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 3 | 2 |
| Buy | 3 | 2 | 1 | 0 | 0 |
| Hold | 3 | 2 | 2 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 11 | 9 | 9 | 3 | 3 |
In the current month, KPTIQ has received 2 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. KPTIQ average Analyst price target in the past 3 months is 5.84.
KPTIQ Financial Forecast
KPTIQ Sales Forecast
Next quarter’s sales forecast for KPTIQ is $0 with a range of ― to ―. The previous quarter’s sales results were ―. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
KPTIQ Stock Forecast FAQ
What is KPTIQ’s average 12-month price target, according to analysts?
Based on analyst ratings, Karyopharm Therapeutics’s 12-month average price target is $5.84.
What is KPTIQ’s upside potential, based on the analysts’ average price target?
Karyopharm Therapeutics has 34252.94% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is KPTIQ a Buy, Sell or Hold?
Karyopharm Therapeutics has a consensus rating of Moderate Buy which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.
What is Karyopharm Therapeutics’s price target?
The average price target for Karyopharm Therapeutics is $5.84. This is based on 3 12-month price targets, issued in the past 3 months. The highest analyst price target is $8.00, the lowest forecast is $3.68. The average price target represents a 34252.94% increase from the current price of $0.017.
What do analysts say about Karyopharm Therapeutics?
Karyopharm Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Street analysts.
How can I buy shares of KPTIQ?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
